Sun Y, Pumroy R, Mallik L, Chaudhuri A, Wang C, Hwang D
Proc Natl Acad Sci U S A. 2025; 122(2):e2416992122.
PMID: 39786927
PMC: 11745410.
DOI: 10.1073/pnas.2416992122.
Altenburg A, Morley J, Bauer J, Walz J, Boyle L
Wellcome Open Res. 2024; 9:113.
PMID: 38800518
PMC: 11126903.
DOI: 10.12688/wellcomeopenres.20738.1.
Jiang J, Natarajan K, Margulies D
IUCrJ. 2024; 11(Pt 3):287-298.
PMID: 38656309
PMC: 11067752.
DOI: 10.1107/S2052252524002768.
Sun Y, Papadaki G, Devlin C, Danon J, Young M, Winters T
Sci Adv. 2023; 9(8):eade7151.
PMID: 36827371
PMC: 9956121.
DOI: 10.1126/sciadv.ade7151.
Wingbermuhle S, Schafer L
RSC Adv. 2022; 12(46):29908-29914.
PMID: 36321080
PMC: 9580618.
DOI: 10.1039/d2ra05324a.
Structural mechanism of tapasin-mediated MHC-I peptide loading in antigen presentation.
Jiang J, Taylor D, Kim E, Boyd L, Ahmad J, Mage M
Nat Commun. 2022; 13(1):5470.
PMID: 36115831
PMC: 9482634.
DOI: 10.1038/s41467-022-33153-8.
TAPBPR employs a ligand-independent docking mechanism to chaperone MR1 molecules.
McShan A, Devlin C, Papadaki G, Sun Y, Green A, Morozov G
Nat Chem Biol. 2022; 18(8):859-868.
PMID: 35725941
PMC: 9703140.
DOI: 10.1038/s41589-022-01049-9.
Chaperones and Catalysts: How Antigen Presentation Pathways Cope With Biological Necessity.
Margulies D, Taylor D, Jiang J, Boyd L, Ahmad J, Mage M
Front Immunol. 2022; 13:859782.
PMID: 35464465
PMC: 9022212.
DOI: 10.3389/fimmu.2022.859782.
The glycosylation status of MHC class I molecules impacts their interactions with TAPBPR.
Tudor Ilca F, Boyle L
Mol Immunol. 2021; 139:168-176.
PMID: 34543843
PMC: 8524320.
DOI: 10.1016/j.molimm.2021.09.007.
Exchange catalysis by tapasin exploits conserved and allele-specific features of MHC-I molecules.
Lan H, Abualrous E, Sticht J, Fernandez L, Werk T, Weise C
Nat Commun. 2021; 12(1):4236.
PMID: 34244493
PMC: 8271027.
DOI: 10.1038/s41467-021-24401-4.
Partnering for the major histocompatibility complex class II and antigenic determinant requires flexibility and chaperons.
Sadegh-Nasseri S
Curr Opin Immunol. 2021; 70:112-121.
PMID: 34146954
PMC: 8373735.
DOI: 10.1016/j.coi.2021.05.005.
TAPBPR promotes antigen loading on MHC-I molecules using a peptide trap.
McShan A, Devlin C, Morozov G, Overall S, Moschidi D, Akella N
Nat Commun. 2021; 12(1):3174.
PMID: 34039964
PMC: 8154891.
DOI: 10.1038/s41467-021-23225-6.
Making Insulin and Staying Out of Autoimmune Trouble: The Beta-Cell Conundrum.
Carre A, Mallone R
Front Immunol. 2021; 12:639682.
PMID: 33854508
PMC: 8039383.
DOI: 10.3389/fimmu.2021.639682.
Super-Enhancer Associated Five-Gene Risk Score Model Predicts Overall Survival in Multiple Myeloma Patients.
Qi T, Qu J, Tu C, Lu Q, Li G, Wang J
Front Cell Dev Biol. 2020; 8:596777.
PMID: 33344452
PMC: 7744621.
DOI: 10.3389/fcell.2020.596777.
Atomistic structure and dynamics of the human MHC-I peptide-loading complex.
Fisette O, Schroder G, Schafer L
Proc Natl Acad Sci U S A. 2020; 117(34):20597-20606.
PMID: 32788370
PMC: 7456110.
DOI: 10.1073/pnas.2004445117.
A loop structure allows TAPBPR to exert its dual function as MHC I chaperone and peptide editor.
Sagert L, Hennig F, Thomas C, Tampe R
Elife. 2020; 9.
PMID: 32167472
PMC: 7117912.
DOI: 10.7554/eLife.55326.
Peptide cargo tunes a network of correlated motions in human leucocyte antigens.
Hopkins J, Crean R, Catici D, Sewell A, Arcus V, van der Kamp M
FEBS J. 2020; 287(17):3777-3793.
PMID: 32134551
PMC: 8651013.
DOI: 10.1111/febs.15278.
Molecular determinants of chaperone interactions on MHC-I for folding and antigen repertoire selection.
McShan A, Devlin C, Overall S, Park J, Toor J, Moschidi D
Proc Natl Acad Sci U S A. 2019; 116(51):25602-25613.
PMID: 31796585
PMC: 6926029.
DOI: 10.1073/pnas.1915562116.
Distinct Polymorphisms in HLA Class I Molecules Govern Their Susceptibility to Peptide Editing by TAPBPR.
Tudor Ilca F, Drexhage L, Brewin G, Peacock S, Boyle L
Cell Rep. 2019; 29(6):1621-1632.e3.
PMID: 31693900
PMC: 7057265.
DOI: 10.1016/j.celrep.2019.09.074.
The lipid transfer protein Saposin B does not directly bind CD1d for lipid antigen loading.
Shamin M, Benedyk T, Graham S, Deane J
Wellcome Open Res. 2019; 4:117.
PMID: 31667358
PMC: 6807164.
DOI: 10.12688/wellcomeopenres.15368.2.